• Skip to primary navigation
  • Skip to main content

National Forum

  • Home
  • About
    • Advisory Leadership Council
    • Board of Directors
    • History
    • National Forum Awards
    • Team
    • Support
  • Collaborations
    • Counter Cholesterol™
    • Million Hearts®
    • Move with the Mayor™
    • Signature Reports
    • Stronger Hearts™
    • Value & Access
      • Value & Innovation Forum
    • World Heart Day
  • Events
    • Heart Failure Roundtable
    • 2020 Annual Meeting
    • Value & Innovation Forum
    • Meeting Archives
      • 2020 Mid-Year Meeting
      • 2019 Annual Meeting
      • 2019 Virtual Convening on Stroke
      • 2019 Mid-Year Member Meeting
      • 2018 Annual Meeting
      • 2018 Mid Year Meeting
  • Members
    • Membership
  • Newsroom
  • Search Toggle
  • Skip to content

Immediate Past National Forum Board Chair, Dr. Jennifer Robinson, lead author on Updated Guidance from the NLA Identifying Patients in Which PCSK9i Use Provides Reasonable Value

Posted on 05.21.19

During it’s 2019 Scientific Sessions, the National Lipid Association (NLA) released a statement paper, led by Dr. Jennifer Robinson, Immediate Past National Forum Board Chair. The paper provides updated guidance to clinicians with identifying patient groups in which use of PCSK9 monoclonal antibodies (mAbs)  provides a reasonable value. Read the full press release here. Access the manuscript and other resources here.

Dr. Robinson also chairs the National Forum’s Value & Access initiative, designed to improve access to evidence-based cardiovascular care.

Categories: In the News, Value & Access

1150 Connecticut Ave., NW, Suite 300, Washington, DC 20036 Phone: (866) 894-3500
Copyright © 2021 National Forum for Heart Disease & Stroke Prevention. All Rights Reserved
  • Facebook
  • Twitter